GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study

  • Mani Ramzi Department of Medical Oncology and Hematology & Bone marrow Transplantaion, Namazi Hospital, Shiraz University of Medical Science Shiraz, Iran.
  • Aliraza Rezvani Mail Department of Medical Oncology and Hematology & Bone marrow Transplantaion, Namazi Hospital, Shiraz University of Medical Science Shiraz, Iran.
  • Mehdi Dehghani Department of Medical Oncology and Hematology & Bone marrow Transplantaion, Namazi Hospital, Shiraz University of Medical Science Shiraz, Iran.
Keywords:
Hodgkin Lymphoma, Relapsed Hodgkin Lymphoma, Salvage Chemotherapy

Abstract

Background: Despite multiple published studies reporting result of salvage regimens for relapsed and refractory Hodgkin’s lymphoma, there are no comparisons of different combinations.
Patients and methods: A Total of 44 patients identified with refractory or relapsed Hodgkin’s Lymphoma were considered eligible for this study. The Patients were randomly divided into two groups of 22, one of which were treated with GDP regimen (gemcitabine, dexamethasone and cisplatin) and the other with EHSAP regimen (etoposide, methyl prednisolone, cisplatin and cytarabine) in a prospective manner. The results of each group were compared.
Results: There were 27.3% complete response, 31.8% more than 50% response, and 40.9% no response with GDP. ESHAP results were 29.5%, 24% and 45.5%, respectively. 
Conclusion: There is no significant difference in response rate between GDP and ESHAP regimens as salvage
chemotherapy in refractory or relapsed Hodgkin’s Lymphoma.

How to Cite
1.
Ramzi M, Rezvani A, Dehghani M. GDP versus ESHAP Regimen in Relapsed and/or Refractory Hodgkin lymphoma: A Comparison Study. Int J Hematol Oncol Stem Cell Res. 9(1):10-14.
QRcode
Section
Articles